Manhattan, NY.  Team Draft will be touring Mt. Sinai in Manhattan, New York City, NY.  Co-Founder Chris Draft will be sitting down with Dr. David Yankelevitz to discuss the centers lung screening program as well as Dr. Yankelevitz’s work with diagnostic software, including techniques for rapid assessment of pulmonary lesion volumes scanned by CT.

The distinguished multidisciplinary lung cancer team at Mount Sinai provides unparalleled diagnostics and treatment for all stages of lung cancer and mesothelioma. With more than 20 years of pioneering research and advancements in treatments, the Mount Sinai physicians were at the forefront of studies demonstrating that annual CT scans can detect up to 85 percent of lung cancers at their earliest and most treatable stages. Additionally, they are renowned for their extraordinary expertise in minimally invasive surgery, such as the VATS lobectomy, and they work tirelessly to improve patients' outcomes and their quality of life.

Dr. Yankelevitz is an experienced thoracic radiologist with a focus on fine needle aspirations (FNAs) of lung lesions that is one of the largest FNA practices in the United States. 

His main academic interest is in the area of diagnosis of early lung cancer.  He was one of the initiators of the International Early Lung Cancer Action Program (I-ELCAP) lung screening study, which now has enrolled over 50,000 people in eight countries worldwide.